Real-world impact of a subsidy decision of sofosbuvir-velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes.

Chee Kiat TanXue-Shi LuoBenjamin Shao-Kiat OngLiang LinKwong-Hoe Ng

Published in: JGH open : an open access journal of gastroenterology and hepatology (2022)

The subsidy decision led to increased accessibility to patients and intended changes in clinical practice. Sofosbuvir-velpatasvir was also clinically effective in the real world. These findings augur well for the continued eradication of chronic hepatitis C infection in Singapore.

Keyphrases

clinical practice
hepatitis c virus
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
decision making
liver fibrosis
hepatitis c virus infection
helicobacter pylori infection
combination therapy
light emitting